Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xvivo Perfusion AB ( (SE:XVIVO) ) has provided an announcement.
XVIVO Perfusion reported largely flat full-year 2025 net sales of SEK 812.2 million, with modest 4 percent growth in local currencies and 3 percent organic growth, as strong 30 percent growth in the Abdominal business offset weaker Thoracic and Services performance and lower revenues from heart trials. Profitability remained solid with a 74 percent gross margin and unchanged EBIT of SEK 88.4 million, but net profit fell sharply to SEK 25.2 million due to negative currency effects, while elevated R&D investments of SEK 152.8 million and use of a credit facility weighed on cash flow, underscoring the company’s continued push to expand its technology platform despite near-term earnings pressure.
The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK236.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company specializing in organ preservation and perfusion solutions used in thoracic and abdominal transplantation, with a product and service portfolio focused on improving transplant outcomes and supporting organ recovery procedures worldwide.
Average Trading Volume: 151,777
Technical Sentiment Signal: Sell
Current Market Cap: SEK6.89B
For an in-depth examination of XVIVO stock, go to TipRanks’ Overview page.